EnvisionRxPlus Silver PDP for Maine Seniors
| CMS Rating: |  |
|---|---|
| Plan Premium: | $34.00 |
| Pharmacy Co-Pay: | $325.00 |
| Initial Coverage Limit: | $2,970.00 |
| Pharmacy Mail Order: | No |
| Gap Coverage: | No Gap Coverage |
| Low Income Subsidy: | Yes |
| Medicare Formulary: | 2446 |
| PDP ID No: | S7694-001 |
| Plan Year: | 2013 |
| Approved by CMS for: | ME Residents |
| Rx Plan Type: | National |
| Members in Region: | 502 |
2013 Medicare Prescription Drug Plan Overview
EnvisionRxPlus Silver (PDP) is an approved Medicare Prescription Drug Plan for Maine seniors.
The annual premium is $408.00 ($34.00 monthly), and it carries a $325.00 deductible on all prescribed medications. For 2013, the maximum Part D deductible is $325. That's up just $5 from last year.
The EnvisionRx Plus formulary ID for this plan is 00012376, and it features 2446 FDA approved medications.
For all Maine seniors with Medicare benefits, there are two situations will change the amount you pay for you drug plan. First, if you qualify for the Extra Help program your premium may be lower. Second, if a premium penalty has been imposed on you for late entry, your premium will be a bit higher.
Here are a few Part D Plans that compare with EnvisionRxPlus Silver:
- Medco Medicare Prescription Plan - Value at $49.10 per month for Maine Seniors
- Medco Medicare Prescription Plan - Choice at $81.40 per month for Maine Seniors
- WellCare Classic at $33.50 per month for Maine Seniors
EnvisionRxPlus Silver Initial Coverage
ICP - the Initial Coverage Phase - is where you share the cost of your prescriptions with your insurance company. You and the carrier each pay your share until you hit the Initial Coverage Limit (ICL). In 2013, the ICL is $2,970. This number is adjusted each year. This plan has a deductible that you must pay before ICP cost-sharing ICP begins.
All prescription drugs fall into one of several tiers within the insurance carrier's drug formulary. Carrier use the formulary tiers to manage cost-sharing. Be aware that tiers are not standardized. In other words, carriers assign drugs to the tier they deem most suitable.
The pharmacy co-pay with the EnvisionRxPlus Silver (PDP) plan in Maine is tiered as follows:
| Tier | Co-Pay Amount | Medications in Tier |
|---|---|---|
| 1 | 25% | 554 Preferred Generics |
| 2 | 25% | 1051 Non-Preferred Generics |
| 3 | 25% | 204 Preferred Brand Drugs |
| 4 | 25% | 431 Non-Preferred Brand Drugs |
| 5 | 25% | 206 Specialty Drugs |
The Initial Coverage Limit (ICL) is $2,970.00. This drug plan offers the full LIS benefit ($0.00 monthly premium) for seniors with Medicare benefits.
EnvisionRxPlus Silver (PDP) 2013 Coverage Gap
The prescription drug Coverage Gap (aka, "Donut Hole") is the coverage phase where you must pay all of your medication costs. You can learn more about costs in the donut hole by reading What is the Medicare Part D Donut Hole? When you reach the donut hole with the EnvisionRxPlus Silver (PDP) plan all depends on your prescriptions.
The Gap Coverage with this policy: You must pay the $3727.50.
Plan Members
Nation wide, the number of seniors using the EnvisionRxPlus Silver policy is 297,366. In region 1 (your region) there are approximately 502 people with this policy (based on 2011 CMS statistics).
Related Medicare Benefits in ME
More Information About EnvisionRx Plus
EnvisionRx Plus is a Medicare-approved Prescription Drug Plan that is available in 50 states and the District of Columbia. EnvisionRx Plus is designed to give Medicare beneficiaries access to affordable generic or brand medications you need. This web site will provide you with important information regarding benefits and services, how much you will have to pay out of your own pocket, and other necessary plan requirements which will help you in making an informed decision about your Medicare Part D prescription drug coverage.
The summary (overall) rating for this EnvisionRx Plus plan is 2.5 out of 5 based on reviews from 502 user ratings from the previous year. For more information about the review process, visit http://cms.gov.
